The New Pharma Playbook: How Assembled Intelligence is Betting on AI

NEW YORK, NY – June 25, 2026 – In a move that signals a deeper strategic current running through the life sciences sector, Assembled Intelligence, a unified healthcare communications platform, has announced it is formally elevating its artificial intelligence practice. This isn't another company simply adding an AI-powered chatbot or a new analytics dashboard; it's a fundamental restructuring of its business model, punctuated by the appointment of Chuck Hemann to the newly created role of Chief Business and AI Officer. The announcement formalizes a capability the company has quietly spent three years building and serves as a declaration that for the high-stakes world of pharmaceutical development and commercialization, AI is no longer a feature—it's the new foundation.

From Feature to Foundation: A New Operating Model

The distinction Assembled Intelligence is making is critical. While most organizations apply AI at the point of commercialization to optimize marketing spend or sales outreach, the firm is embedding it far earlier and more broadly across the entire product lifecycle. This integrated approach weaves AI into the fabric of evidence synthesis, medical education, brand strategy, and payer communications. The goal is to move beyond isolated efficiencies and create a compounding effect where insights from one stage inform and accelerate the next.

At the heart of this capability is a proprietary disease-area intelligence engine. According to the company, this system synthesizes a vast array of inputs—from published clinical evidence and real-world data to behavioral science and competitive intelligence—into what it calls “decision-ready intelligence.” This allows teams working across clinical development, medical affairs, and market access to operate from a common, continuously updated wellspring of information. The strategic implication is a significant reduction in the time it takes to move from complex data to clear, actionable strategy.

“This is an inflection point for Assembled Intelligence — and for the industry,” said Mark Lydiatt, the company's CEO. “The power of these integrated AI platforms now enables us to evolve and innovate existing services in ways that deliver stronger outcomes for clients... It's also opening entirely new service models that weren't economically or practically feasible before.” Lydiatt’s statement frames the move not as an incremental improvement, but as a paradigm shift. By declaring AI as “the operating model we’re already running,” he positions the company as a frontrunner in a sector grappling with overwhelming data velocity and complexity.

The Human-in-the-Loop Imperative

To lead this charge, the company has tapped Chuck Hemann, a veteran in applying data analytics to healthcare challenges. His appointment underscores the firm's core philosophy: AI is a tool to amplify, not replace, human expertise. This human-centric approach is arguably the most crucial component of their strategy, especially within the heavily regulated and scientifically nuanced life sciences industry where context is everything and errors can have profound consequences.

“What we've built is different: it starts with domain expertise—the science, the payer logic, the patient, caregiver, and HCP experience, the brand strategy, the creative instinct—and uses AI to make that expertise faster to apply and harder to replicate,” Hemann stated. His vision directly counters the narrative of AI as a job-killer or a simple efficiency layer. “AI doesn't replace the judgment of great strategists, scientists, and creatives. It amplifies it. The moment it becomes just another efficiency layer is the moment it stops being a strategic asset. We're here to make sure that doesn't happen.”

This philosophy is operationalized by ensuring that the AI tools are wielded by specialists, not generalists. The platform's model relies on its scientists, medical writers, and market access strategists to use the AI to augment their deep domain knowledge. This sidesteps the “black box” problem, where opaque algorithms generate conclusions without clear rationale. By keeping an expert in the loop, the system maintains the interpretability and accountability required for navigating the FDA, communicating with payers, and educating physicians. The dedicated AI team Hemann now leads, which includes Harry Sharman, Alyssa Marone, and Jake Pistotnik, is supported by a growing network of embedded AI leads across every discipline, tasked with driving adoption and weaving automation into daily workflows.

The Capital Behind the Capability

Such an ambitious technological and cultural transformation requires significant resources, and Assembled Intelligence is backed by Amulet Capital Partners, a middle-market private equity firm focused exclusively on the healthcare sector. This is not incidental. The backing of a specialized investor like Amulet provides more than just capital; it offers a stamp of validation from financiers who understand the unique challenges and opportunities within healthcare. Their investment signals confidence that Assembled Intelligence's model—combining deep domain expertise with a sophisticated, integrated AI infrastructure—is a winning formula for future growth.

The partnership enables the company to accelerate investment in its AI infrastructure and expand the practice's reach across its growing roster of biopharma and biotech clients. In an economic environment where capital is increasingly discerning, Amulet’s focused bet suggests a broader trend: private equity is moving beyond simple roll-ups and looking to fund companies that are building durable, technology-driven competitive advantages. For Assembled Intelligence, this financial backing provides the runway needed to scale its operations and fully realize its vision of an AI-native communications platform.

Navigating the High-Stakes AI Frontier

Assembled Intelligence's strategic pivot is a direct response to the immense pressures facing the life sciences industry. Pharmaceutical companies are in a perpetual race to bring drugs to market faster and more efficiently, all while navigating an increasingly complex web of scientific data, regulatory requirements, and market access hurdles. The traditional agency model, reliant on manual data synthesis and siloed teams, is struggling to keep pace. The ability to rapidly process clinical trial results, real-world evidence, and payer policies is no longer a luxury but a necessity for survival.

However, the path is fraught with challenges. Data privacy, regulatory compliance for AI-generated communications, and the need for explainable models are significant barriers to entry. The company’s three-year head start in building a compliant infrastructure and integrated workflows may prove to be a formidable moat. By building its systems with the regulatory and scientific realities of the sector in mind from day one, the firm is positioning itself not just as an innovator, but as a trusted partner in a field where trust is the ultimate currency. This deliberate, foundational work is what separates a sustainable strategy from a superficial marketing claim, marking a significant evolution in how the engines of the global healthcare economy are being built.